Allergan PLC. (NYSE:AGN) Position Reduced by Berkshire Asset Management LLC PA

Berkshire Asset Management LLC PA cut its stake in shares of Allergan PLC. (NYSE:AGN) by 3.3% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,852 shares of the company’s stock after selling 64 shares during the period. Berkshire Asset Management LLC PA’s holdings in Allergan PLC. were worth $450,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in the stock. Veritas Asset Management LLP bought a new position in shares of Allergan PLC. during the first quarter valued at approximately $761,339,000. Edgewood Management LLC raised its position in shares of Allergan PLC. by 7.0% in the first quarter. Edgewood Management LLC now owns 2,704,211 shares of the company’s stock valued at $646,090,000 after buying an additional 178,055 shares in the last quarter. Epoch Investment Partners Inc. raised its position in shares of Allergan PLC. by 3.8% in the first quarter. Epoch Investment Partners Inc. now owns 2,013,415 shares of the company’s stock valued at $481,045,000 after buying an additional 73,081 shares in the last quarter. UBS Asset Management Americas Inc. raised its position in shares of Allergan PLC. by 0.3% in the first quarter. UBS Asset Management Americas Inc. now owns 1,995,281 shares of the company’s stock valued at $476,713,000 after buying an additional 5,042 shares in the last quarter. Finally, Blue Ridge Capital L.L.C. raised its position in shares of Allergan PLC. by 24.1% in the first quarter. Blue Ridge Capital L.L.C. now owns 1,909,900 shares of the company’s stock valued at $456,313,000 after buying an additional 370,400 shares in the last quarter. Institutional investors own 84.77% of the company’s stock.

Allergan PLC. (NYSE AGN) traded up 0.31% during midday trading on Friday, reaching $232.91. The company’s stock had a trading volume of 960,958 shares. Allergan PLC. has a 1-year low of $184.50 and a 1-year high of $256.80. The company has a market capitalization of $78.07 billion, a price-to-earnings ratio of 7.10 and a beta of 1.16. The company’s 50-day moving average price is $246.34 and its 200-day moving average price is $238.00.

Allergan PLC. (NYSE:AGN) last announced its quarterly earnings results on Thursday, August 3rd. The company reported $4.02 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.95 by $0.07. Allergan PLC. had a return on equity of 7.25% and a net margin of 79.17%. The company had revenue of $4.01 billion during the quarter, compared to analyst estimates of $3.95 billion. During the same quarter in the previous year, the firm posted $3.35 EPS. The firm’s quarterly revenue was up 8.8% on a year-over-year basis. On average, analysts predict that Allergan PLC. will post $16.27 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 15th. Stockholders of record on Friday, August 18th will be issued a $0.70 dividend. The ex-dividend date of this dividend is Wednesday, August 16th. This represents a $2.80 annualized dividend and a dividend yield of 1.21%. Allergan PLC.’s dividend payout ratio (DPR) is 9.95%.

ILLEGAL ACTIVITY WARNING: “Allergan PLC. (NYSE:AGN) Position Reduced by Berkshire Asset Management LLC PA” was originally posted by Community Financial News and is owned by of Community Financial News. If you are accessing this story on another domain, it was stolen and republished in violation of international copyright and trademark legislation. The legal version of this story can be viewed at https://www.com-unik.info/2017/08/11/allergan-plc-nyseagn-position-reduced-by-berkshire-asset-management-llc-pa.html.

AGN has been the topic of several recent analyst reports. BidaskClub lowered shares of Allergan PLC. from a “buy” rating to a “hold” rating in a research note on Wednesday. Citigroup Inc. reiterated a “focus list” rating and issued a $261.27 price target (up from $184.50) on shares of Allergan PLC. in a research note on Friday, April 21st. Deutsche Bank AG reiterated a “buy” rating and issued a $273.00 price target (up from $265.00) on shares of Allergan PLC. in a research note on Monday, July 17th. Goldman Sachs Group, Inc. (The) lowered shares of Allergan PLC. from a “buy” rating to a “neutral” rating and set a $262.00 price target on the stock. in a research note on Wednesday, May 10th. Finally, Royal Bank Of Canada increased their price target on shares of Allergan PLC. from $279.00 to $284.00 and gave the company an “outperform” rating in a research note on Wednesday, May 10th. Eight investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. Allergan PLC. currently has an average rating of “Buy” and an average price target of $274.49.

In other news, Director Nesli Basgoz sold 1,889 shares of the company’s stock in a transaction on Thursday, May 18th. The stock was sold at an average price of $220.45, for a total value of $416,430.05. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.36% of the company’s stock.

Allergan PLC. Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

What are top analysts saying about Allergan PLC.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Allergan PLC. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit